High Risk of Severe Anaemia after Antimalarial Treatment in G6PD Deficient Patients
Author Information
Author(s): Fanello Caterina I., Karema Corine, Avellino Pamela, Bancone Germana, Uwimana Aline, Lee Sue J., d'Alessandro Umberto, Modiano David
Primary Institution: Centre for Vaccinology and Tropical Medicine, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom
Hypothesis
Does chlorproguanil-dapsone+artesunate treatment increase the risk of severe anaemia in patients with G6PD deficiency?
Conclusion
Chlorproguanil-dapsone+artesunate has a poor safety profile in individuals with G6PD deficiency, leading to a higher risk of severe anaemia.
Supporting Evidence
- Patients with G6PD deficiency had a mean haematocrit decline of 1.94% per day after treatment with CD+A.
- 10 patients required blood transfusions due to severe post-treatment haemolysis.
- G6PD deficiency increased the risk of severe anaemia following treatment with CD+A by a factor of 10.2.
Takeaway
Some kids with a certain gene problem can get really sick from a malaria medicine that usually helps. It's important to check for this gene before giving the medicine.
Methodology
The study evaluated the safety of two antimalarial treatments in a randomized clinical trial with children genotyped for G6PD deficiency.
Potential Biases
Potential bias in patient selection and treatment allocation in the clinical trial.
Limitations
The study may not generalize to all populations due to its specific demographic and geographic focus.
Participant Demographics
Children aged 6-59 months with uncomplicated malaria, including both G6PD deficient and normal patients.
Statistical Information
P-Value
0.04
Confidence Interval
95% CI 1.8 to 59.3
Statistical Significance
p=0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website